An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 24, 2017

Study Completion Date

August 24, 2017

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Deflazacort

Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.

Trial Locations (4)

14642

University of Rochester, Rochester

60611

Lurie Children's Hospital, Chicago

84112

University of Utah, Salt Lake City

90095

UCLA, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT02295748 - An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort | Biotech Hunter | Biotech Hunter